{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:51:12Z","timestamp":1794333072504,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Long-term survivors after pancreatic resection for PDAC are rare, constituting a specific subset of patients that remains poorly understood. This study aims to identify the clinic-pathological, molecular, and therapeutic factors for predicting long-term survival (LTS). A systematic review and random-effect meta-analysis were conducted. Inclusion criteria were PDAC histology, resected patients, studies reporting risk factors, and comparing two groups. The primary endpoint was to evaluate predictive factors for LTS in patients with PDAC who underwent\u00a0surgery. Results were reported with the Mantel\u2013Haenszel random effects model using Risk Ratio (RR) or Mean Difference (MD). Meta-regression analysis was used to clarify heterogeneity. Nineteen studies, involving a total of 5412 patients, were included: 1097 (20,3%) in group LTS and 4334 (79,7%) in group STS (short-term survivors). These factors were associated to LTS: small size (RR 1.53, 95% IC 1.14; 2.05); T1-T2 stage (RR 1.07, 95% IC 1.03; 1.11); N0 (RR 1.82, 95% IC 1.60; 2.09); AJCC Stage I (RR 2.28 95% IC 1.87; 2.79); low-grade G1-2 (RR 1.21, 95% IC 1.09; 1.34); R0 resection (RR 1.11, 95% IC 1.08; 1.13); low levels of CEA (MD \u2212\u00a04.41, 95% IC \u2212\u00a06.23; \u2212\u00a02.59) and Ca 19.9 (MD \u2212\u00a066.4, 95% IC: \u2212\u00a071.9; \u2212\u00a060.9); absence of perineural invasion (RR 0.93, 95% IC: 0.90; 0.96), lymph-vascular invasion (RR 0.87, 95% IC: 0.83; 0.91), venous invasion (RR 0.63, 95% IC: 0.48; 0.83) and perioperative transfusions (RR 0.56, 95% IC: 0.40; 0.79). Several factors are associated with an LTS. They can be considered reliable indicators for predicting tumor progression.<\/jats:p>","DOI":"10.1007\/s13304-025-02382-z","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:22:32Z","timestamp":1756732952000},"page":"509-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive factors for long-term survival in pancreatic ductal adenocarcinoma that underwent surgery: a systematic review and meta-analysis of literature"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5859-1543","authenticated-orcid":false,"given":"Vincenzo","family":"D\u2019Ambra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6638-4479","authenticated-orcid":false,"given":"Claudio","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Ingaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2382_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913\u20132921","journal-title":"Cancer Res"},{"issue":"10242","key":"2382_CR2","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, Surana R, Valle JW et al (2020) Pancreatic cancer. Lancet 395(10242):2008\u20132020","journal-title":"Lancet"},{"issue":"10","key":"2382_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.dld.2018.08.009","volume":"50","author":"A Barhli","year":"2018","unstructured":"Barhli A, Cros J, Bartholin L et al (2018) Prognostic stratification of resected pancreatic ductal adenocarcinoma: past, present and future. Dig Liver Dis 50(10):979\u2013990","journal-title":"Dig Liver Dis"},{"key":"2382_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pharmthera.2015.08.006","volume":"155","author":"C Neuzillet","year":"2015","unstructured":"Neuzillet C, Tijeras-Raballand A, Bourget P et al (2015) State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 155:80\u2013104","journal-title":"Pharmacol Ther"},{"key":"2382_CR5","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JPTGS Higgins","year":"2011","unstructured":"Higgins JPTGS (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, London"},{"key":"2382_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T et al (2007) Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak 7:16","journal-title":"BMC Med Inform Decis Mak"},{"key":"2382_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"issue":"1","key":"2382_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13304-024-02039-3","volume":"77","author":"V D\u2019Ambra","year":"2025","unstructured":"D\u2019Ambra V, Ingaldi C, Ricci C et al (2025) Pancreatic cancer and long survivors: a survey of Italian society of oncological surgery (SICO). Update Surg 77(1):57\u201364","journal-title":"Update Surg"},{"issue":"9","key":"2382_CR9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73(9):712\u2013716","journal-title":"ANZ J Surg"},{"key":"2382_CR10","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719\u2013748","journal-title":"J Natl Cancer Inst"},{"key":"2382_CR11","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"2382_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/sim.1752","volume":"23","author":"JP Higgins","year":"2004","unstructured":"Higgins JP, Thompson SG (2004) Controlling the risk from spurious findings from meta-regression. Stat Med 23:1663\u20131682","journal-title":"Stat Med"},{"key":"2382_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"issue":"2","key":"2382_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2):455\u2013463","journal-title":"Biometrics"},{"issue":"3","key":"2382_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0039-6060(97)90128-8","volume":"122","author":"F Mosca","year":"1997","unstructured":"Mosca F, Giulianotti PC, Balestracci T et al (1997) Long-term survival in pancreatic cancer: pylorus-preserving versus Whipple pancreatoduodenectomy. Surgery 122(3):553\u2013566","journal-title":"Surgery"},{"issue":"9","key":"2382_CR16","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/j.1572-0241.2001.04123.x","volume":"96","author":"NA Ahmad","year":"2001","unstructured":"Ahmad NA, Lewis JD, Ginsberg GG et al (2001) Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 96(9):2609\u20132615","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2382_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/SLA.0b013e3181613142","volume":"247","author":"T Schnelldorfer","year":"2008","unstructured":"Schnelldorfer T, Ware AL, Sarr MG et al (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247(3):456\u2013462","journal-title":"Ann Surg"},{"issue":"4","key":"2382_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s11605-007-0384-8","volume":"12","author":"CR Ferrone","year":"2008","unstructured":"Ferrone CR, Brennan MF, Gonen M et al (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12(4):701\u2013706","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"2382_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00268-008-9807-2","volume":"33","author":"M Ueda","year":"2009","unstructured":"Ueda M, Endo I, Nakashima M et al (2009) Prognostic factors after resection of pancreatic cancer. World J Surg 33(1):104\u2013110","journal-title":"World J Surg"},{"issue":"3","key":"2382_CR20","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.surg.2012.05.020","volume":"152","author":"CR Ferrone","year":"2012","unstructured":"Ferrone CR, Pieretti-Vanmarcke R, Bloom JP et al (2012) Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery 152(3):S43\u2013S49","journal-title":"Surgery"},{"issue":"1","key":"2382_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1477-2574.2012.00571.x","volume":"15","author":"R Lewis","year":"2013","unstructured":"Lewis R, Drebin JA, Callery MP et al (2013) A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB 15(1):49\u201360","journal-title":"HPB"},{"issue":"4","key":"2382_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2011.12.020","volume":"38","author":"SM Robinson","year":"2012","unstructured":"Robinson SM, Rahman A, Haugk B et al (2012) Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma. Eur J Surg Oncol 38(4):333\u2013339","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"2382_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s00534-011-0466-6","volume":"19","author":"Y Nimura","year":"2012","unstructured":"Nimura Y, Nagino M, Takao S et al (2012) Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19(3):230\u2013241","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"2382_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/jso.23409","volume":"108","author":"M Sinn","year":"2013","unstructured":"Sinn M, Striefler JK, Sinn BV et al (2013) Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. J Surg Oncol 108(6):398\u2013402","journal-title":"J Surg Oncol"},{"issue":"4","key":"2382_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/MPA.0000000000000063","volume":"43","author":"SH Shin","year":"2014","unstructured":"Shin SH, Kim SC, Hong SM et al (2014) Can statistically determind prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?: Clinicopathological analysis of 82 long-term survivors. Pancreas 43(4):571\u2013577","journal-title":"Pancreas"},{"issue":"1","key":"2382_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3748\/wjg.v21.i1.262","volume":"21","author":"T Yamamoto","year":"2015","unstructured":"Yamamoto T, Yagi S, Kinoshita H et al (2015) Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol 21(1):262\u2013268","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2382_CR27","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1245\/s10434-016-5716-z","volume":"24","author":"VJ Picozzi","year":"2017","unstructured":"Picozzi VJ, Oh SY, Edwards A et al (2017) Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol 24(6):1722\u20131730","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2382_CR28","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/cam4.1178","volume":"6","author":"Y Nakano","year":"2017","unstructured":"Nakano Y, Kitago M, Shinoda M et al (2017) Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study. Cancer Med 6(10):2278\u20132286","journal-title":"Cancer Med"},{"issue":"6","key":"2382_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00423-018-1709-7","volume":"403","author":"K Nakagawa","year":"2018","unstructured":"Nakagawa K, Akahori T, Nishiwada S et al (2018) Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 403(6):693\u2013700","journal-title":"Langenbecks Arch Surg"},{"issue":"5","key":"2382_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.pan.2019.06.012","volume":"19","author":"N Kasahara","year":"2019","unstructured":"Kasahara N, Noda H, Kakizawa N et al (2019) A lack of postoperative complications after pancreatectomy contributes to the long-term survival of patients with pancreatic cancer. Pancreatology 19(5):686\u2013694","journal-title":"Pancreatology"},{"issue":"3","key":"2382_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.hbpd.2020.12.006","volume":"20","author":"AM Luu","year":"2021","unstructured":"Luu AM, Braumann C, Belyaev O et al (2021) Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 20(3):271\u2013278","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"2382_CR32","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.surg.2022.11.015","volume":"173","author":"G Malleo","year":"2023","unstructured":"Malleo G, Maggino L, Lionetto G et al (2023) A dynamic analysis of empirical survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma. Surgery 173(4):1030\u20131038","journal-title":"Surgery"},{"issue":"13","key":"2382_CR33","doi-asserted-by":"publisher","first-page":"8249","DOI":"10.1245\/s10434-021-10401-7","volume":"28","author":"G Belfiori","year":"2021","unstructured":"Belfiori G, Crippa S, Francesca A et al (2021) Long-term survivors after upfront resection for pancreatic ductal adenocarcinoma: an actual 5-year analysis of disease-specific and post-recurrence survival. Ann Surg Oncol 28(13):8249\u20138260","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2382_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien P (2004) Classification of surgical complications. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"issue":"6","key":"2382_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ags3.12597","volume":"6","author":"T Hata","year":"2022","unstructured":"Hata T, Chiba K, Mizuma M et al (2022) Levels of tumor markers CEA\/CA 19\u20139 in serum and peritoneal lavage predict postoperative recurrence in patients with pancreatic cancer. Ann Gastroenterol Surg 6(6):862\u2013872","journal-title":"Ann Gastroenterol Surg"},{"issue":"10","key":"2382_CR36","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.3390\/cancers12102970","volume":"12","author":"L van Manen","year":"2020","unstructured":"van Manen L, Groen JV, Putter H et al (2020) Stage-specific value of carbohydrate antigen 19\u20139 and carcinoembryonic antigen serum levels on survival and recurrence in pancreatic cancer: a single center study and meta-analysis. Cancers (Basel). 12(10):2970","journal-title":"Cancers (Basel)."},{"key":"2382_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.01.012","author":"Y Kato","year":"2019","unstructured":"Kato Y, Yamada S, Tashiro M et al (2019) Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. HPB (Oxford). https:\/\/doi.org\/10.1016\/j.hpb.2019.01.012","journal-title":"HPB (Oxford)"},{"issue":"2","key":"2382_CR38","first-page":"99","volume":"9","author":"G Garcea","year":"2008","unstructured":"Garcea G, Dennison AR, Pattenden CJ et al (2008) Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP 9(2):99\u2013132","journal-title":"JOP"},{"issue":"12","key":"2382_CR39","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1002\/wjs.12397","volume":"48","author":"C Ingaldi","year":"2024","unstructured":"Ingaldi C, D\u2019Ambra V, Ricci C et al (2024) Clinicopathological predictive factors in long-term survivors who underwent surgery for pancreatic ductal adenocarcinoma: a single-center propensity score matched analysis. World J Surg 48(12):3001\u20133013","journal-title":"World J Surg"},{"key":"2382_CR40","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.hbpd.2020.12.006","volume":"20","author":"AM Luu","year":"2021","unstructured":"Luu AM, Braumann C, Belayaev O et al (2021) Long-term survival after pancreaticoduodenectomy in patients with ductal adenocarcinoma of the pancreatic head. Hepatobiliary Pancreat Dis Int 20:271\u2013278","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2382_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000019327","author":"ZJ Zheng","year":"2020","unstructured":"Zheng ZJ, Wang MJ, Tan CL et al (2020) Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/md.0000000000019327","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2382_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00268-002-6659-z","volume":"27","author":"A Richter","year":"2003","unstructured":"Richter A, Niedergethmann M, Sturm JW et al (2003) Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 27(3):324\u2013329","journal-title":"World J Surg"},{"key":"2382_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijsu.2018.01.021","volume":"51","author":"R Casadei","year":"2018","unstructured":"Casadei R, Ricci C, Taffurelli G et al (2018) Multicolour versus monocolour inking specimens after pancreaticoduodenectomy for periampullary cancer: a single centre prospective randomised clinical trial. Int J Surg 51:63\u201370","journal-title":"Int J Surg"},{"key":"2382_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ctrv.2017.03.003","volume":"55","author":"S Schorn","year":"2017","unstructured":"Schorn S, Demir IE, Reyes CM et al (2017) The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - a systematic review and meta-analysis. Cancer Treat Rev 55:96\u2013106","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"2382_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S et al (2023) Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 8(2):157\u2013168","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"2382_CR46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","volume":"19","author":"MA Tempero","year":"2021","unstructured":"Tempero MA, Malafa MP, Al-Hawary M et al (2021) Pancreatic adenocarcinoma, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 19(4):439\u2013457","journal-title":"J Natl Compr Canc Netw"},{"issue":"25","key":"2382_CR47","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Canadian Cancer Trials Group and the Unicancer-GI\u2013PRODIGE Group, Conroy T, Hammel P, Hebbar M et al (2018) FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379(25):2395\u20132406","journal-title":"N Engl J Med"},{"issue":"18","key":"2382_CR48","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703","journal-title":"N Engl J Med"},{"issue":"10","key":"2382_CR49","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.dld.2018.08.009","volume":"50","author":"A Barhli","year":"2018","unstructured":"Barhli A, Cros J, Bartholin L et al (2018) Prognostic stratification of resected pancreatic ductal adenocarcinoma: past, present, and future. Dig Liver Dis 50(10):979\u2013990","journal-title":"Dig Liver Dis"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02382-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02382-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:02:23Z","timestamp":1779814943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02382-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2382"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02382-z","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"PROSPERO 2023 CRD42023472753.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration and protocol"}},{"value":"This study is a meta-analysis based on previously published data and did not involve any direct research with human participants or animals. Therefore, ethical approval was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was not required for this type of study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}